Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas

British Journal of Haematology

Volumn 168, Issue 6, 2015, Pages 771-783

  Boi, Michela ^a,b   Zucca, Emanuele ^c   Inghirami, Giorgio ^a,b,d   Bertoni, Francesco ^c,e  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^d UNIVERSITY OF TURIN   (Italy)

^e INSTITUTE OF ONCOLOGY RESEARCH   (Switzerland)

Author keywords

anaplastic lymphoma kinase; Crizotinib; JAK; Lymphoma; PRDM1

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 4 [[(4 METHYLPHENYL)SULFONYLOXY]ACETAMIDO]SALICYLIC ACID; 5 AZA 2' DEOXYCYTIDINE; 5 CHLORO 4 [[2 (ISOPROPYLSULFONYL)PHENYL]AMINO] 2 [[2 METHOXY 4 [4 (4 METHYL 1 PIPERAZINYL) 1 PIPERIDINYL]PHENYL]AMINO]PYRIMIDINE; 7 HYDROXYSTAUROSPORINE; ABT 236; ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; ASP 3060; B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; BRENTUXIMAB VEDOTIN; CD30 ANTIGEN; CERITINIB; CRIZOTINIB; GELDANAMYCIN; GSK 1838705; HERBIMYCIN A; IMATINIB; JANUS KINASE; MIDKINE; MITOGEN ACTIVATED PROTEIN KINASE; PF 956980; PHOSPHATIDYLINOSITOL 3 KINASE; PLEIOTROPHIN; RAS PROTEIN; STAT3 PROTEIN; TANESPIMYCIN; TEMSIROLIMUS; UNCLASSIFIED DRUG; [2 [[5 CHLORO 2 [[4 [4 (DIMETHYLAMINO) 1 PIPERIDINYL] 2 METHOXYPHENYL]AMINO] 4 PYRIMIDINYL]AMINO]PHENYL]DIMETHYLPHOSPHINE OXIDE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ALK GENE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CELLULAR DISTRIBUTION; CLINICAL FEATURE; DRUG EFFICACY; ENZYME ACTIVATION; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENE REARRANGEMENT; GENE TARGETING; GENE TRANSLOCATION; GENETIC VARIABILITY; HISTOLOGY; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; MOLECULARLY TARGETED THERAPY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; GENETICS; IMMUNOPHENOTYPING; LYMPHOMA, LARGE-CELL, ANAPLASTIC; METABOLISM; PATHOLOGY; PROCEDURES;

ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOPHENOTYPING; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; TRANSLOCATION, GENETIC;

EID: 84924194832     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13265     Document Type: Review

References (105)

1. Adrada, B.E., Miranda, R.N., Rauch, G.M., Arribas, E., Kanagal-Shamanna, R., Clemens, M.W., Fanale, M., Haideri, N., Mustafa, E., Larrinaga, J., Reisman, N.R., Jaso, J., You, M.J., Young, K.H., Medeiros, L.J. & Yang, W. (2014) Breast implant-associated anaplastic large cell lymphoma: sensitivity, specificity, and findings of imaging studies in 44 patients. Breast Cancer Research and Treatment, 147, 1-14.
2. Ansell, S.M., Horwitz, S.M., Engert, A., Khan, K.D., Lin, T., Strair, R., Keler, T., Graziano, R., Blanset, D., Yellin, M., Fischkoff, S., Assad, A. & Borchmann, P. (2007) Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. Journal of Clinical Oncology, 25, 2764-2769.
3. Armitage, J.O. (2012) The aggressive peripheral T-cell lymphomas: 2012 update on diagnosis, risk stratification, and management. American Journal of Hematology, 87, 511-519.
4. Bitter, M.A., Franklin, W.A., Larson, R.A., McKeithan, T.W., Rubin, C.M., Le Beau, M.M., Stephens, J.K. & Vardiman, J.W. (1990) Morphology in Ki-1(CD30)-positive non-Hodgkin's lymphoma is correlated with clinical features and the presence of a unique chromosomal abnormality, t(2;5)(p23;q35). American Journal of Surgical Pathology, 14, 305-316.
5. Bohling, S.D., Jenson, S.D., Crockett, D.K., Schumacher, J.A., Elenitoba-Johnson, K.S. & Lim, M.S. (2008) Analysis of gene expression profile of TPM3-ALK positive anaplastic large cell lymphoma reveals overlapping and unique patterns with that of NPM-ALK positive anaplastic large cell lymphoma. Leukemia Research, 32, 383-393.
6. Boi, M., Stathis, A., Zucca, E., Inghirami, G. & Bertoni, F. (2012) Genetic alterations in systemic nodal and extranodal non-cutaneous lymphomas derived from mature T cells and natural killer cells. Cancer Science, 103, 1397-1404.
7. Boi, M., Rinaldi, A., Kwee, I., Bonetti, P., Todaro, M., Tabbo, F., Piva, R., Rancoita, P.M., Matolcsy, A., Timar, B., Tousseyn, T., Rodriguez-Pinilla, S.M., Piris, M.A., Bea, S., Campo, E., Bhagat, G., Swerdlow, S.H., Rosenwald, A., Ponzoni, M., Young, K.H., Piccaluga, P.P., Dummer, R., Pileri, S., Zucca, E., Inghirami, G. & Bertoni, F. (2013) PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. Blood, 122, 2683-2693.
8. Bowden, E.T., Stoica, G.E. & Wellstein, A. (2002) Anti-apoptotic signaling of pleiotrophin through its receptor, anaplastic lymphoma kinase. Journal of Biological Chemistry, 277, 35862-35868.
9. Brugieres, L., Pacquement, H., Le Deley, M.C., Leverger, G., Lutz, P., Paillard, C., Baruchel, A., Frappaz, D., Nelken, B., Lamant, L. & Patte, C. (2009) Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Pediatric Oncology. Journal of Clinical Oncology, 27, 5056-5061.
10. Cannella, S., Santoro, A., Bruno, G., Pillon, M., Mussolin, L., Mangili, G., Rosolen, A. & Arico, M. (2007) Germline mutations of the perforin gene are a frequent occurrence in childhood anaplastic large cell lymphoma. Cancer, 109, 2566-2571.
11. Changelian, P.S., Moshinsky, D., Kuhn, C.F., Flanagan, M.E., Munchhof, M.J., Harris, T.M., Whipple, D.A., Doty, J.L., Sun, J., Kent, C.R., Magnuson, K.S., Perregaux, D.G., Sawyer, P.S. & Kudlacz, E.M. (2008) The specificity of JAK3 kinase inhibitors. Blood, 111, 2155-2157.
12. Chiarle, R., Voena, C., Ambrogio, C., Piva, R. & Inghirami, G. (2008a) The anaplastic lymphoma kinase in the pathogenesis of cancer. Nature Reviews Cancer, 8, 11-23.
13. Chiarle, R., Martinengo, C., Mastini, C., Ambrogio, C., D'Escamard, V., Forni, G. & Inghirami, G. (2008b) The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination. Nature Medicine, 14, 676-680.
14. Chomarat, P., Banchereau, J., Davoust, J. & Palucka, A.K. (2000) IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nature Immunology, 1, 510-514.
15. Ciambotti, B., Mussolin, L., d'Amore, E.S., Pillon, M., Sieni, E., Coniglio, M.L., Ros, M.D., Cetica, V., Arico, M. & Rosolen, A. (2014) Monoallelic mutations of the perforin gene may represent a predisposing factor to childhood anaplastic large cell lymphoma. Journal of Pediatric Hematology/Oncology, 36, e359-e365.
16. Colleoni, G.W., Bridge, J.A., Garicochea, B., Liu, J., Filippa, D.A. & Ladanyi, M. (2000) ATIC-ALK: a novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35). American Journal of Pathology, 156, 781-789.
17. Cools, J., Wlodarska, I., Somers, R., Mentens, N., Pedeutour, F., Maes, B., De Wolf-Peeters, C., Pauwels, P., Hagemeijer, A. & Marynen, P. (2002) Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor. Genes Chromosomes Cancer, 34, 354-362.
18. Couronne, L., Scourzic, L., Pilati, C., Della Valle, V., Duffourd, Y., Solary, E., Vainchenker, W., Merlio, J.P., Beylot-Barry, M., Damm, F., Stern, M.H., Gaulard, P., Lamant, L., Delabesse, E., Merle-Beral, H., Nguyen-Khac, F., Fontenay, M., Tilly, H., Bastard, C., Zucman-Rossi, J., Bernard, O.A. & Mercher, T. (2013) STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model. Haematologica, 98, 1748-1752.
19. Crescenzo, R., Abate, F., Lasorsa, E., Tabbo, F., Gaudiano, M., Chiesa, N., Di Giacomo, F., Spaccarotella, E., Barbarossa, L., Todaro, M., Boi, M., Tousseyn, T., Rosenwald, A., Kenner, L., Rossi, D., Mevellec, L., Vialard, J.E., Bertoni, F., Rabadan, R. & Inghirami, G. (2014) Convergent mutations and new kinase fusions lead to oncogenic STAT3 activation in Anaplastic Large Cell Lymphoma. Blood (ASH Annual Meeting Abstracts), 124.
20. Debelenko, L.V., Arthur, D.C., Pack, S.D., Helman, L.J., Schrump, D.S. & Tsokos, M. (2003) Identification of CARS-ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor. Laboratory Investigation, 83, 1255-1265.
21. Delsol, G., Ralfkiaer, E., Stein, H., Wright, D. & Jaffe, E.S. (2001) Anaplastic large cell lymphoma. In: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues (ed. by E.S. Jaffe, N.L. Harris, H. Stein & J.W. Vardiman ), pp. 230-235. IARC Press, Lyon.
22. Delsol, G., Falini, B., Muller-Hermelink, H.K., Campo, E., Jaffe, E.S., Gascoyne, R., Stein, H. & Kinney, M.C. (2008) Anaplastic large cell lymphoma (ALCL), ALK-positive. In: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues (ed. by S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, A. Pileri, H. Stein, J. Thiele & J.W. Vardiman ), pp. 312-316. IARC Press, Lyon.
23. Desjobert, C., Renalier, M.H., Bergalet, J., Dejean, E., Joseph, N., Kruczynski, A., Soulier, J., Espinos, E., Meggetto, F., Cavaille, J., Delsol, G. & Lamant, L. (2011) MiR-29a down-regulation in ALK-positive anaplastic large cell lymphomas contributes to apoptosis blockade through MCL-1 overexpression. Blood, 117, 6627-6637.
24. Falini, B., Pileri, S., Pizzolo, G., Durkop, H., Flenghi, L., Stirpe, F., Martelli, M.F. & Stein, H. (1995) CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood, 85, 1-14.
25. Falini, B., Pileri, S., Zinzani, P.L., Carbone, A., Zagonel, V., Wolf-Peeters, C., Verhoef, G., Menestrina, F., Todeschini, G., Paulli, M., Lazzarino, M., Giardini, R., Aiello, A., Foss, H.D., Araujo, I., Fizzotti, M., Pelicci, P.G., Flenghi, L., Martelli, M.F. & Santucci, A. (1999) ALK+ lymphoma: clinico-pathological findings and outcome. Blood, 93, 2697-2706.
26. Feldman, A.L., Law, M., Remstein, E.D., Macon, W.R., Erickson, L.A., Grogg, K.L., Kurtin, P.J. & Dogan, A. (2009) Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas. Leukemia, 23, 574-580.
27. Feldman, A.L., Law, M.E., Inwards, D.J., Dogan, A., McClure, R.F. & Macon, W.R. (2010) PAX5-positive T-cell anaplastic large cell lymphomas associated with extra copies of the PAX5 gene locus. Modern Pathology, 23, 593-602.
28. Feldman, A.L., Dogan, A., Smith, D.I., Law, M.E., Ansell, S.M., Johnson, S.H., Porcher, J.C., Ozsan, N., Wieben, E.D., Eckloff, B.W. & Vasmatzis, G. (2011) Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood, 117, 915-919.
29. Forde, P.M. & Rudin, C.M. (2012) Crizotinib in the treatment of non-small-cell lung cancer. Expert Opinion on Pharmacotherapy, 13, 1195-1201.
30. Forero-Torres, A., Leonard, J.P., Younes, A., Rosenblatt, J.D., Brice, P., Bartlett, N.L., Bosly, A., Pinter-Brown, L., Kennedy, D., Sievers, E.L. & Gopal, A.K. (2009) A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. British Journal of Haematology, 146, 171-179.
31. Galkin, A.V., Melnick, J.S., Kim, S., Hood, T.L., Li, N., Li, L., Xia, G., Steensma, R., Chopiuk, G., Jiang, J., Wan, Y., Ding, P., Liu, Y., Sun, F., Schultz, P.G., Gray, N.S. & Warmuth, M. (2007) Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proceedings of the National Academy of Sciences of the USA, 104, 270-275.
32. Gascoyne, R.D., Aoun, P., Wu, D., Chhanabhai, M., Skinnider, B.F., Greiner, T.C., Morris, S.W., Connors, J.M., Vose, J.M., Viswanatha, D.S., Coldman, A. & Weisenburger, D.D. (1999) Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood, 93, 3913-3921.
33. George, S.K., Vishwamitra, D., Manshouri, R., Shi, P. & Amin, H.M. (2014) The ALK inhibitor ASP3026 eradicates NPM-ALK(+) T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model. Oncotarget, 5, 5750-5763.
34. Han, Y., Amin, H.M., Frantz, C., Franko, B., Lee, J., Lin, Q. & Lai, R. (2006) Restoration of shp1 expression by 5-AZA-2′-deoxycytidine is associated with downregulation of JAK3/STAT3 signaling in ALK-positive anaplastic large cell lymphoma. Leukemia, 20, 1602-1609.
35. Harris, N.L., Jaffe, E.S., Stein, H., Banks, P.M., Chan, J.K., Cleary, M.L., Delsol, G., De Wolf-Peeters, C., Falini, B. & Gatter, K.C. (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood, 84, 1361-1392.
36. Hernandez, L., Pinyol, M., Hernandez, S., Bea, S., Pulford, K., Rosenwald, A., Lamant, L., Falini, B., Ott, G., Mason, D.Y., Delsol, G. & Campo, E. (1999) TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. Blood, 94, 3265-3268.
37. Iqbal, J., Weisenburger, D.D., Greiner, T.C., Vose, J.M., McKeithan, T., Kucuk, C., Geng, H., Deffenbacher, K., Smith, L., Dybkaer, K., Nakamura, S., Seto, M., Delabie, J., Berger, F., Loong, F., Au, W.Y., Ko, Y.H., Sng, I., Armitage, J.O. & Chan, W.C. (2010) Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood, 115, 1026-1036.
38. Iqbal, J., Wright, G., Wang, C., Rosenwald, A., Gascoyne, R.D., Weisenburger, D.D., Greiner, T.C., Smith, L., Guo, S., Wilcox, R.A., Teh, B.T., Lim, S.T., Tan, S.Y., Rimsza, L.M., Jaffe, E.S., Campo, E., Martinez, A., Delabie, J., Braziel, R.M., Cook, J.R., Tubbs, R.R., Ott, G., Geissinger, E., Gaulard, P., Piccaluga, P.P., Pileri, S.A., Au, W.Y., Nakamura, S., Seto, M., Berger, F., de Leval, L., Connors, J.M., Armitage, J., Vose, J., Chan, W.C., Staudt, L.M. & Lymphoma Leukemia Molecular Profiling Project and the International Peripheral T-cell Lymphoma Project. (2014) Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood, 123, 2915-2923.
39. Kaneko, Y., Frizzera, G., Edamura, S., Maseki, N., Sakurai, M., Komada, Y., Tanaka, H., Sasaki, M. & Suchi, T. (1989) A novel translocation, t(2;5)(p23;q35), in childhood phagocytic large T-cell lymphoma mimicking malignant histiocytosis. Blood, 73, 806-813.
40. Karube, K., Nakagawa, M., Tsuzuki, S., Takeuchi, I., Honma, K., Nakashima, Y., Shimizu, N., Ko, Y.H., Morishima, Y., Ohshima, K., Nakamura, S. & Seto, M. (2011) Identification of FOXO3 and PRDM1 as tumor-suppressor gene candidates in NK-cell neoplasms by genomic and functional analyses. Blood, 118, 3195-3204.
41. Kinney, M.C., Higgins, R.A. & Medina, E.A. (2011) Anaplastic large cell lymphoma: twenty-five years of discovery. Archives of Pathology and Laboratory Medicine, 135, 19-43.
42. Kucuk, C., Iqbal, J., Hu, X., Gaulard, P., De Leval, L., Srivastava, G., Au, W.Y., McKeithan, T.W. & Chan, W.C. (2011) PRDM1 is a tumor suppressor gene in natural killer cell malignancies. Proceedings of the National Academy of Sciences of the USA, 108, 20119-20124.
43. Lamant, L., Dastugue, N., Pulford, K., Delsol, G. & Mariame, B. (1999) A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation. Blood, 93, 3088-3095.
44. Lamant, L., Gascoyne, R.D., Duplantier, M.M., Armstrong, F., Raghab, A., Chhanabhai, M., Rajcan-Separovic, E., Raghab, J., Delsol, G. & Espinos, E. (2003) Non-muscle myosin heavy chain (MYH9): a new partner fused to ALK in anaplastic large cell lymphoma. Genes Chromosomes Cancer, 37, 427-432.
45. Lamant, L., de Reynies, A., Duplantier, M.M., Rickman, D.S., Sabourdy, F., Giuriato, S., Brugieres, L., Gaulard, P., Espinos, E. & Delsol, G. (2007) Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. Blood, 109, 2156-2164.
46. Le Beau, M.M., Bitter, M.A., Larson, R.A., Doane, L.A., Ellis, E.D., Franklin, W.A., Rubin, C.M., Kadin, M.E. & Vardiman, J.W. (1989) The t(2;5)(p23;q35): a recurring chromosomal abnormality in Ki-1-positive anaplastic large cell lymphoma. Leukemia, 3, 866-870.
47. Le Deley, M.C., Rosolen, A., Williams, D.M., Horibe, K., Wrobel, G., Attarbaschi, A., Zsiros, J., Uyttebroeck, A., Marky, I.M., Lamant, L., Woessmann, W., Pillon, M., Hobson, R., Mauguen, A., Reiter, A. & Brugieres, L. (2010) Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial. Journal of Clinical Oncology, 28, 3987-3993.
48. Lechner, M.G., Megiel, C., Church, C.H., Angell, T.E., Russell, S.M., Sevell, R.B., Jang, J.K., Brody, G.S. & Epstein, A.L. (2012) Survival signals and targets for therapy in breast implant-associated ALK- anaplastic large cell lymphoma. Clinical Cancer Research, 18, 4549-4559.
49. Li, R. & Morris, S.W. (2008) Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy. Medicinal Research Reviews, 28, 372-412.
50. Lindsley, C.W. (2010) The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation: a 2009 update. Current Topics in Medicinal Chemistry, 10, 458-477.
51. Liu, C., Iqbal, J., Teruya-Feldstein, J., Shen, Y., Dabrowska, M.J., Dybkaer, K., Lim, M.S., Piva, R., Barreca, A., Pellegrino, E., Spaccarotella, E., Lachel, C.M., Kucuk, C., Jiang, C.S., Hu, X., Bhagavathi, S., Greiner, T.C., Weisenburger, D.D., Aoun, P., Perkins, S.L., McKeithan, T.W., Inghirami, G. & Chan, W.C. (2013) MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma. Blood, 122, 2083-2092.
52. Lu, K.V., Jong, K.A., Kim, G.Y., Singh, J., Dia, E.Q., Yoshimoto, K., Wang, M.Y., Cloughesy, T.F., Nelson, S.F. & Mischel, P.S. (2005) Differential induction of glioblastoma migration and growth by two forms of pleiotrophin. Journal of Biological Chemistry, 280, 26953-26964.
53. Lu, Y., Zhao, X., Wang, E., Chen, W. & Huang, Q. (2010) ALK-negative anaplastic large cell lymphoma with extensive peripheral blood and bone marrow involvements manifested as "leukemic phase". Leukemia Research, 34, 475-482.
54. Ma, Z., Hill, D.A., Collins, M.H., Morris, S.W., Sumegi, J., Zhou, M., Zuppan, C. & Bridge, J.A. (2003) Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor. Genes Chromosomes Cancer, 37, 98-105.
55. Maes, B., Vanhentenrijk, V., Wlodarska, I., Cools, J., Peeters, B., Marynen, P. & de Wolf-Peeters, C. (2001) The NPM-ALK and the ATIC-ALK fusion genes can be detected in non-neoplastic cells. American Journal of Pathology, 158, 2185-2193.
56. Mandelbaum, J., Bhagat, G., Tang, H., Mo, T., Brahmachary, M., Shen, Q., Chadburn, A., Rajewsky, K., Tarakhovsky, A., Pasqualucci, L. & Dalla-Favera, R. (2010) BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. Cancer Cell, 18, 568-579.
57. Marino-Enriquez, A. & Dal Cin, P. (2013) ALK as a paradigm of oncogenic promiscuity: different mechanisms of activation and different fusion partners drive tumors of different lineages. Cancer Genetics, 206, 357-373.
58. Mason, D.Y. (2007) Innovations in immunohistochemistry for the haematopathologist. Annales de Pathologie, 27 Spec No 1, 1S33-1S36.
59. Mehrotra, M., Medeiros, L.J., Luthra, R., Sargent, R.L., Yao, H., Barkoh, B.A., Singh, R. & Patel, K.P. (2014) Identification of putative pathogenic microRNA and its downstream targets in anaplastic lymphoma kinase-negative anaplastic large cell lymphoma. Human Pathology, 45, 1995-2005.
60. Merkel, O., Hamacher, F., Laimer, D., Sifft, E., Trajanoski, Z., Scheideler, M., Egger, G., Hassler, M.R., Thallinger, C., Schmatz, A., Turner, S.D., Greil, R. & Kenner, L. (2010) Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma. Proceedings of the National Academy of Sciences of the USA, 107, 16228-16233.
61. Merkel, O., Hamacher, F., Sifft, E., Kenner, L. & Greil, R. (2011) Novel therapeutic options in anaplastic large cell lymphoma: molecular targets and immunological tools. Molecular Cancer Therapeutics, 10, 1127-1136.
62. Mesaros, E.F., Burke, J.P., Parrish, J.D., Dugan, B.J., Anzalone, A.V., Angeles, T.S., Albom, M.S., Aimone, L.D., Quail, M.R., Wan, W., Lu, L., Huang, Z., Ator, M.A., Ruggeri, B.A., Cheng, M., Ott, G.R. & Dorsey, B.D. (2011) Novel 2, 3, 4, 5-tetrahydro-benzo[d]azepine derivatives of 2, 4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse models. Bioorganic & Medicinal Chemistry Letters, 21, 463-466.
63. Miranda, R.N., Aladily, T.N., Prince, H.M., Kanagal-Shamanna, R., de Jong, D., Fayad, L.E., Amin, M.B., Haideri, N., Bhagat, G., Brooks, G.S., Shifrin, D.A., O'Malley, D.P., Cheah, C.Y., Bacchi, C.E., Gualco, G., Li, S., Keech, J.A. Jr, Hochberg, E.P., Carty, M.J., Hanson, S.E., Mustafa, E., Sanchez, S., Manning, J.T. Jr, Xu-Monette, Z.Y., Miranda, A.R., Fox, P., Bassett, R.L., Castillo, J.J., Beltran, B.E., de Boer, J.P., Chakhachiro, Z., Ye, D., Clark, D., Young, K.H. & Medeiros, L.J. (2014) Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. Journal of Clinical Oncology, 32, 114-120.
64. Morris, S.W., Kirstein, M.N., Valentine, M.B., Dittmer, K.G., Shapiro, D.N., Saltman, D.L. & Look, A.T. (1994) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science, 263, 1281-1284.
65. Mourali, J., Benard, A., Lourenco, F.C., Monnet, C., Greenland, C., Moog-Lutz, C., Racaud-Sultan, C., Gonzalez-Dunia, D., Vigny, M., Mehlen, P., Delsol, G. & Allouche, M. (2006) Anaplastic lymphoma kinase is a dependence receptor whose proapoptotic functions are activated by caspase cleavage. Molecular and Cellular Biology, 26, 6209-6222.
66. Neckers, L. & Workman, P. (2012) Hsp90 molecular chaperone inhibitors: are we there yet? Clinical Cancer Research, 18, 64-76.
67. Ohgami, R.S., Ma, L., Monabati, A., Zehnder, J.L. & Arber, D.A. (2014) STAT3 mutations are present in aggressive B-cell lymphomas including a subset of diffuse large B-cell lymphomas with CD30 expression. Haematologica, 99, e105-e107.
68. Oltersdorf, T., Elmore, S.W., Shoemaker, A.R., Armstrong, R.C., Augeri, D.J., Belli, B.A., Bruncko, M., Deckwerth, T.L., Dinges, J., Hajduk, P.J., Joseph, M.K., Kitada, S., Korsmeyer, S.J., Kunzer, A.R., Letai, A., Li, C., Mitten, M.J., Nettesheim, D.G., Ng, S., Nimmer, P.M., O'Connor, J.M., Oleksijew, A., Petros, A.M., Reed, J.C., Shen, W., Tahir, S.K., Thompson, C.B., Tomaselli, K.J., Wang, B., Wendt, M.D., Zhang, H., Fesik, S.W. & Rosenberg, S.H. (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature, 435, 677-681.
69. Panagopoulos, I., Nilsson, T., Domanski, H.A., Isaksson, M., Lindblom, P., Mertens, F. & Mandahl, N. (2006) Fusion of the SEC31L1 and ALK genes in an inflammatory myofibroblastic tumor. International Journal of Cancer, 118, 1181-1186.
70. Parrilla Castellar, E.R., Jaffe, E.S., Said, J.W., Swerdlow, S.H., Ketterling, R.P., Knudson, R.A., Sidhu, J.S., Hsi, E.D., Karikehalli, S., Jiang, L., Vasmatzis, G., Gibson, S.E., Ondrejka, S., Nicolae, A., Grogg, K.L., Allmer, C., Ristow, K.M., Wilson, W.H., Macon, W.R., Law, M.E., Cerhan, J.R., Habermann, T.M., Ansell, S.M., Dogan, A., Maurer, M.J. & Feldman, A.L. (2014) ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood, 124, 1473-1480.
71. Pasqualucci, L., Compagno, M., Houldsworth, J., Monti, S., Grunn, A., Nandula, S.V., Aster, J.C., Murty, V.V., Shipp, M.A. & Dalla-Favera, R. (2006) Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. Journal of Experimental Medicine, 203, 311-317.
72. Passoni, L., Scardino, A., Bertazzoli, C., Gallo, B., Coluccia, A.M., Lemonnier, F.A., Kosmatopoulos, K. & Gambacorti-Passerini, C. (2002) ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8 + T-cell epitopes. Blood, 99, 2100-2106.
73. Perez, K., Castillo, J., Dezube, B.J. & Pantanowitz, L. (2010) Human immunodeficiency virus-associated anaplastic large cell lymphoma. Leukaemia & Lymphoma, 51, 430-438.
74. Pham-Ledard, A., Prochazkova-Carlotti, M., Laharanne, E., Vergier, B., Jouary, T., Beylot-Barry, M. & Merlio, J.P. (2010) IRF4 gene rearrangements define a subgroup of CD30-positive cutaneous T-cell lymphoma: a study of 54 cases. The Journal of Investigative Dermatology, 130, 816-825.
75. Piccaluga, P.P., Gazzola, A., Mannu, C., Agostinelli, C., Bacci, F., Sabattini, E., Sagramoso, C., Piva, R., Roncolato, F., Inghirami, G. & Pileri, S.A. (2010) Pathobiology of anaplastic large cell lymphoma. Advances in Hematology, 345053.
76. Ralfkiaer, E., Willemze, R., Paulli, M. & Kadin, M.E. (2008) Primary cutaneous CD30-positive T-cell lymphopolifearative disorders. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed. by S. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele & J.W. Vardiman ), pp. 300-305. IARC, Lyon.
77. Reisman, N.R. (2014) Breast implant-associated anaplastic large cell lymphoma: what we can do. Aesthetic Surgery Journal, 34, 956-958.
78. Sabbatini, P., Korenchuk, S., Rowand, J.L., Groy, A., Liu, Q., Leperi, D., Atkins, C., Dumble, M., Yang, J., Anderson, K., Kruger, R.G., Gontarek, R.R., Maksimchuk, K.R., Suravajjala, S., Lapierre, R.R., Shotwell, J.B., Wilson, J.W., Chamberlain, S.D., Rabindran, S.K. & Kumar, R. (2009) GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. Molecular Cancer Therapeutics, 8, 2811-2820.
79. Salaverria, I., Bea, S., Lopez-Guillermo, A., Lespinet, V., Pinyol, M., Burkhardt, B., Lamant, L., Zettl, A., Horsman, D., Gascoyne, R., Ott, G., Siebert, R., Delsol, G. & Campo, E. (2008) Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas. British Journal of Haematology, 140, 516-526.
80. Savage, K.J., Harris, N.L., Vose, J.M., Ullrich, F., Jaffe, E.S., Connors, J.M., Rimsza, L., Pileri, S.A., Chhanabhai, M., Gascoyne, R.D., Armitage, J.O. & Weisenburger, D.D. (2008) ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood, 111, 5496-5504.
81. Schmitz, N., Trumper, L., Ziepert, M., Nickelsen, M., Ho, A.D., Metzner, B., Peter, N., Loeffler, M., Rosenwald, A. & Pfreundschuh, M. (2010) Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood, 116, 3418-3425.
82. Schwab, U., Stein, H., Gerdes, J., Lemke, H., Kirchner, H., Schaadt, M. & Diehl, V. (1982) Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature, 299, 65-67.
83. Sebti, S.M. & Hamilton, A.D. (2000) Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene, 19, 6584-6593.
84. Shi, X.L., Tang, X.W. & Wu, D.P. (2011) Research progresses in the pathogenesis of anaplastic large cell lymphoma. Chinese Journal of Cancer, 30, 392-399.
85. Siddiquee, K., Zhang, S., Guida, W.C., Blaskovich, M.A., Greedy, B., Lawrence, H.R., Yip, M.L., Jove, R., McLaughlin, M.M., Lawrence, N.J., Sebti, S.M. & Turkson, J. (2007) Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proceedings of the National Academy of Sciences of the USA, 104, 7391-7396.
86. Skinnider, B.F., Connors, J.M., Sutcliffe, S.B. & Gascoyne, R.D. (1999) Anaplastic large cell lymphoma: a clinicopathologic analysis. Hematological Oncology, 17, 137-148.
87. Soda, M., Choi, Y.L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S., Watanabe, H., Kurashina, K., Hatanaka, H., Bando, M., Ohno, S., Ishikawa, Y., Aburatani, H., Niki, T., Sohara, Y., Sugiyama, Y. & Mano, H. (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 448, 561-566.
88. Spaccarotella, E., Pellegrino, E., Ferracin, M., Ferreri, C., Cuccuru, G., Liu, C., Iqbal, J., Cantarella, D., Taulli, R., Provero, P., Di Cunto, F., Medico, E., Negrini, M., Chan, W.C., Inghirami, G. & Piva, R. (2014) STAT3-mediated activation of microRNA cluster 17~92 promotes proliferation and survival of ALK-positive anaplastic large cell lymphoma. Haematologica, 99, 116-124.
89. Stein, H., Mason, D.Y., Gerdes, J., O'Connor, N., Wainscoat, J., Pallesen, G., Gatter, K., Falini, B., Delsol, G., Lemke, H., Schwarting, L. & Lennert, K. (1985) The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood, 66, 848-858.
90. Stoica, G.E., Kuo, A., Aigner, A., Sunitha, I., Souttou, B., Malerczyk, C., Caughey, D.J., Wen, D., Karavanov, A., Riegel, A.T. & Wellstein, A. (2001) Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. Journal of Biological Chemistry, 276, 16772-16779.
91. Stoica, G.E., Kuo, A., Powers, C., Bowden, E.T., Sale, E.B., Riegel, A.T. & Wellstein, A. (2002) Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. Journal of Biological Chemistry, 277, 35990-35998.
92. Tabbo, F., Barreca, A., Machiorlatti, R., Messana, K., Landra, I., Abate, F., Boi, M., Todaro, M.C., Abele, C., Novero, D., Zamo, A., Chilosi, M., Ponzoni, M., Cheng, M., Ruggeri, B., Piccaluga, P.P., Pileri, S., Tiacci, E., Falini, B., Shultz, L., Piva, R., Medico, E., Bertoni, F., Rabadan, R. & Inghirami, G. (2013) Humanized NOD/Scid/IL2 g-/- tumor grafts recapitulate primary anaplastic large cell lymphoma. Annual Meeting of the American Association for Cancer Research, p. Abstract 3853. AACR, Washington, DC.
93. Takeuchi, K., Choi, Y.L., Togashi, Y., Soda, M., Hatano, S., Inamura, K., Takada, S., Ueno, T., Yamashita, Y., Satoh, Y., Okumura, S., Nakagawa, K., Ishikawa, Y. & Mano, H. (2009) KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clinical Cancer Research, 15, 3143-3149.
94. Thompson, M.A., Stumph, J., Henrickson, S.E., Rosenwald, A., Wang, Q., Olson, S., Brandt, S.J., Roberts, J., Zhang, X., Shyr, Y. & Kinney, M.C. (2005) Differential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinase-negative anaplastic large cell lymphomas. Human Pathology, 36, 494-504.
95. Tilly, H., Gaulard, P., Lepage, E., Dumontet, C., Diebold, J., Plantier, I., Berger, F., Symann, M., Petrella, T., Lederlin, P. & Briere, J. (1997) Primary anaplastic large-cell lymphoma in adults: clinical presentation, immunophenotype, and outcome. Blood, 90, 3727-3734.
96. Tort, F., Pinyol, M., Pulford, K., Roncador, G., Hernandez, L., Nayach, I., Kluin-Nelemans, H.C., Kluin, P., Touriol, C., Delsol, G., Mason, D. & Campo, E. (2001) Molecular characterization of a new ALK translocation involving moesin (MSN-ALK) in anaplastic large cell lymphoma. Laboratory Investigation, 81, 419-426.
97. Touriol, C., Greenland, C., Lamant, L., Pulford, K., Bernard, F., Rousset, T., Mason, D.Y. & Delsol, G. (2000) Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like). Blood, 95, 3204-3207.
98. Tse, C., Shoemaker, A.R., Adickes, J., Anderson, M.G., Chen, J., Jin, S., Johnson, E.F., Marsh, K.C., Mitten, M.J., Nimmer, P., Roberts, L., Tahir, S.K., Xiao, Y., Yang, X., Zhang, H., Fesik, S., Rosenberg, S.H. & Elmore, S.W. (2008) ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Research, 68, 3421-3428.
99. Vasmatzis, G., Johnson, S.H., Knudson, R.A., Ketterling, R.P., Braggio, E., Fonseca, R., Viswanatha, D.S., Law, M.E., Kip, N.S., Ozsan, N., Grebe, S.K., Frederick, L.A., Eckloff, B.W., Thompson, E.A., Kadin, M.E., Milosevic, D., Porcher, J.C., Asmann, Y.W., Smith, D.I., Kovtun, I.V., Ansell, S.M., Dogan, A. & Feldman, A.L. (2012) Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood, 120, 2280-2289.
100. Voena, C. & Chiarle, R. (2012) The battle against ALK resistance: successes and setbacks. Expert Opinion on Investigational Drugs, 21, 1751-1754.
101. Webb, T.R., Slavish, J., George, R.E., Look, A.T., Xue, L., Jiang, Q., Cui, X., Rentrop, W.B. & Morris, S.W. (2009) Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Review of Anticancer Therapy, 9, 331-356.
102. Younes, A., Bartlett, N.L., Leonard, J.P., Kennedy, D.A., Lynch, C.M., Sievers, E.L. & Forero-Torres, A. (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. New England Journal of Medicine, 363, 1812-1821.
103. Zdzalik, D., Dymek, B., Grygielewicz, P., Gunerka, P., Bujak, A., Lamparska-Przybysz, M., Wieczorek, M. & Dzwonek, K. (2014) Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma. Journal of Cancer Research and Clinical Oncology, 140, 589-598.
104. Zettl, A., Rudiger, T., Konrad, M.A., Chott, A., Simonitsch-Klupp, I., Sonnen, R., Muller-Hermelink, H.K. & Ott, G. (2004) Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations. American Journal of Pathology, 164, 1837-1848.
105. Zou, H.Y., Li, Q., Lee, J.H., Arango, M.E., McDonnell, S.R., Yamazaki, S., Koudriakova, T.B., Alton, G., Cui, J.J., Kung, P.P., Nambu, M.D., Los, G., Bender, S.L., Mroczkowski, B. & Christensen, J.G. (2007) An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Research, 67, 4408-4417.